Colorectal cancer study to be discontinued
NuCana has revealed that the NuTide:323 colorectal cancer study is being discontinued following a pre-planned initial analysis and recommendation from the NuTide:323 Study Steering Committee.
The Steering Committee believed that the combination of NUC-3373 with leucovorin, irinotecan and bevacizumab (NUFIRI+bev) was unlikely to achieve the study’s primary objective of superior progression free survival (PFS) compared to the control arm of 5-FU, leucovorin, irinotecan and bevacizumab (FOLFIRI+bev).
In all three arms, the treatment regimens were observed to have a favourable safety profile and to be generally well tolerated, with only 12 of the 175 patients (four patients in each arm) discontinuing treatment due to adverse events.
“While we are disappointed with this unexpected outcome, especially for people living with colorectal cancer, we gained valuable knowledge from the NuTide:323 study which will inform our ongoing development programmes,” said Hugh Griffith, NuCana’s Founder and Chief Executive Officer.
“These results highlight the challenges associated with developing new medicines for patients with complex and heterogenous cancers such as metastatic colorectal cancer. We will leverage insights from these data to identify future potential development options for NUC-3373 in colorectal cancer.”
NuCana says that the decision to discontinue the trial does not impact the ongoing NuTide:303 study, in which NUC-3373 is being combined with either pembrolizumab in solid tumours or docetaxel in patients with lung cancer.
The company also intends to share latest data from the Phase II part of the NuTide:701 study of NUC-7738 in combination with pembrolizumab in patients with melanoma at the ESMO annual conference in September 2024.
Diana Spencer, Senior Digital Content Editor, DDW
